Editas ($EDIT) and BeiGene ($BGNE) may have made it to Nasdaq, but the IPO window isn't open for everyone. Apellis pulled their attempt at going public. The Kentucky biotech had filed for an $86 million offering last fall, as the market began to unwind. Analysts expect that the bar for completing an IPO of any kind has been raised high in the first half of 2016, as biotech shares in particular have come in for a beating. Story